Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros


Bases de dados
Tipo de documento
Intervalo de ano de publicação
1.
Indian J Lepr ; 82(4): 189-94, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21434595

RESUMO

Appearance of new skin and/or nerve lesions during or after fixed duration of multidrug therapy (MDT), in leprosy, is not uncommon. It could be a lesion due to leprosy reaction or relapse. Differentiation is easy in classical reactions both clinically and histopathologically. But, difficult in other situations especially when the relapse cases present with features of reaction at the onset. A study was done to find the reasons for released from treatment (RFT) cases to come to clinic and to follow in terms of clinical and neurological activity, leprosy reactions and deformity progression. Out of them, 14 cases and 86 cases had received paucibacillary (PB) and multibacillary (MB) multidrug therapy respectively. Skin lesions either old or new were noticed in 74% cases which might be due to inactivity or activity were noticed in 74% cases which might be due to inactivity or activity in forms of relapse and reaction. Relapse was seen in 26 cases. Out of these, 10 and 16 cases were previously diagnosed as PB and MB cases respectively. PB cases relapsed into MB cases while MB cases relapsed into MB cases. 46 cases presented with either type 1 or type 2 reaction. After declared as RFT, parasthesia in 34 cases, weakness in 18 cases, paresis and paralytic deformity in 6 cases were seen. So, all the RFT cases need regular follow-up, IEC and physiotherapy to prevent deformity and to diagnose relapse and reactions at the earliest.


Assuntos
Hansenostáticos/uso terapêutico , Hanseníase Multibacilar/tratamento farmacológico , Hanseníase Paucibacilar/tratamento farmacológico , Progressão da Doença , Quimioterapia Combinada , Seguimentos , Humanos , Hanseníase Multibacilar/diagnóstico , Hanseníase Multibacilar/prevenção & controle , Hanseníase Paucibacilar/diagnóstico , Hanseníase Paucibacilar/prevenção & controle , Alta do Paciente , Prevenção Secundária , Pele/patologia , Fatores de Tempo
2.
Indian J Lepr ; 78(3): 231-6, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17120506

RESUMO

A hospital-based prospective study was carried out to assess the frequency of occurrence of leprosy in childhood. Out of 800 patients registered for leprosy, 67 (8.4%) were children aged 4-14 years. The male-to-female ratio was 2.5:1. Family history of leprosy was found in 14.9% of cases. The commonest type of leprosy was BT leprosy (35.8%), followed by BB leprosy (25.4%) and BL leprosy (19.4%). More than half of the patients had more than one lesion. Nerve involvement was noted in 70.1% of cases. Slit-skin smear was positive in 46.3% of cases. Out of 67 children, PB and MB regimens were given to 29 and 38 respectively.


Assuntos
Hanseníase/patologia , Mycobacterium leprae , Adolescente , Criança , Pré-Escolar , Feminino , Hospitalização , Humanos , Índia/epidemiologia , Hanseníase/diagnóstico , Hanseníase/tratamento farmacológico , Hanseníase/epidemiologia , Masculino , Prevalência , Estudos Prospectivos
3.
Indian J Lepr ; 77(3): 217-27, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16353520

RESUMO

A study was carried out from June 1999 to June 2001 to assess the impact of fixed duration multidrug therapy (FD-MDT) in newly detected cases of leprosy in terms of clinical and neurological improvement and changes in the bacillary index of skin smear for AFB. 200 new leprosy cases (both PB & MB) were started on FD-MDT. Of these 200 cases, 16 were of pure neuritic leprosy. After treatment, out of 184 cases with typical skin lesions of leprosy, all 26 PB cases showed inactivity of skin lesions, and, of the remaining 158 MB cases, 40.5% showed inactivity and 59.5% showed complete resolution of skin lesions. Out of 68 skin smear-positive cases, 42 cases with a BI of < or = 3 became smear-negative, while others showed gradual fall in the BI. Such heavily bacilliferous cases were continued with treatment for 1 more year to prevent relapse. As FD-MDT alone does not cure established sensory and motor impairment, it did not show any change in 19% of the patients presented with permanent sensory motor disturbance. FD-MDT prevents progression of sensory/motor disturbance.


Assuntos
Hansenostáticos/uso terapêutico , Hanseníase/tratamento farmacológico , Adolescente , Adulto , Idoso , Criança , Progressão da Doença , Quimioterapia Combinada , Feminino , Humanos , Índia , Hansenostáticos/administração & dosagem , Hanseníase/microbiologia , Hanseníase/patologia , Hanseníase/fisiopatologia , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/prevenção & controle , Mycobacterium leprae/isolamento & purificação , Paralisia/prevenção & controle , Transtornos de Sensação/prevenção & controle , Pele/microbiologia , Pele/patologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA